Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal - Top-Institutions - MDSpire

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal

  • By

  • Qinghua Ke

  • Shiqiong Zhou

  • June 11, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Fred Hutchinson Cancer Research Center
    Fred Hutchinson Cancer Research Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Abramson Cancer Center at the University of Pennsylvania
    Abramson Cancer Center at the University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, NY

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal

  • by Qinghua Ke, Shiqiong Zhou

  • June 11, 2026

Related Content

Efficacy and safety of hyperthermic intraperitoneal chemotherapy in treatment of primary or recurrent ovarian cancer: systematic review and meta-analysis

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS